Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

JHEP reports : innovation in hepatology - 1 Aug 2026

Kah Janine, Staffeldt Lisa, Stefanski Svenja, Herzog Natalie, Mattert Gregor, Volz Tassilo, Voß Maximilian, Schulze Kornelius, Heumann Asmus, Dammermann Werner, Kammerer Sarah, Küpper Jan-Heiner, Villavicencio-Lorini Pablo, Dandri Maura, Lüth Stefan

Abstract excerpt

BACKGROUND & AIMS: HBV-associated hepatocellular carcinoma (HCC) is characterized by immune evasion and heterogeneous responses to immunotherapy. However, the mechanisms driving tumor-immune tolerance and their impact on checkpoint inhibitor-based therapies remain poorly understood. To address this gap, we generated a patient-derived HBV-induced HCC cell line that preserves a clinically relevant immune evasion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to HLA-G Antigens

Share to Immune Evasion

Share to Immune Tolerance

Share to Immunotherapy

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 42107532
DOI: 10.1016/j.jhepr.2026.101891
PMCID: PMC13352049

Genes

IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.PMID 42107532Read ↗

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.Semantic proximity Read ↗

Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles.Semantic proximity Read ↗

NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions.Semantic proximity Read ↗

Immune-checkpoint HLA-G gene polymorphisms, 3'-UTR types and their association with hepatocellular carcinoma and treatment response in Indian population.Semantic proximity Read ↗

Neoantigens as potential vaccines in hepatocellular carcinomaSemantic proximity Read ↗

Immune and Mutational Profile of Gene-Edited Low-Immunogenic Human Primary Cholangiocyte OrganoidsSemantic proximity Read ↗

Impairing NK-mediated immune rejection through NKG2DL editing to improve CAR-T cell persistenceSemantic proximity Read ↗

Distinct Single-cell Immune Ecosystems Distinguish True and <i>De Novo</i> HBV-related Hepatocellular Carcinoma RecurrencesSemantic proximity Read ↗

Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencingSemantic proximity Read ↗

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaSemantic proximity Read ↗

Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesSemantic proximity Read ↗

Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.